Sawai Receives Approvals for 4 Generic Drugs with 13 Strengths
Osaka, Japan – August 17, 2020 – Sawai Pharmaceutical Co., Ltd. (Sawai, Head office: Osaka, Japan, President: Kenzo Sawai) received approvals by the Ministry of Health, Labour and Welfare for 4 generic drugs with 13 strengths. The 2 compounds marked with an asterisk below are approved for the first time as generics.
The list of approved products:
1. Pregabalin OD Tablets, Capsules
|
Generic name: |
Pregabalin* |
|
Strengths: |
OD Tablets, Capsules: 25mg, 75mg, 150mg |
|
Brand products: |
Lyrica® OD Tablets 25mg, 75mg, 150mg, Lyrica® Capsules 25mg, 75mg, 150mg |
2. Rivastigmine Tapes
|
Generic name: |
Rivastigmine* |
|
Strengths: |
4.5mg, 9mg, 13.5mg, 18mg |
|
Brand products: |
EXELON® PATCH 4.5mg, 9mg, 13.5mg, 18mg, RIVASTACH® Patches 4.5mg, 9mg, 13.5mg, 18mg |
3. Bortezomib for Injection
|
Generic name: |
Bortezomib |
|
Strengths: |
3mg |
|
Brand products: |
VELCADE® Injection 3mg |
4. Famotidine Intravenous Injection
|
Generic name: |
Famotidine |
|
Strengths: |
10mg, 20mg |
|
Brand products: |
Gaster® Injection 10mg, 20mg |
The products announced in this press release are not approved by the Food & Drug Administration for sale and distribution in the United States.